“When there are at least five such reports, we will put information on our website about the type of reactions that have occurred,” the agency’s Chief Physician Maija Kaukonen told the broadcaster, adding that no further details could be disclosed due to patient confidentiality.

The United Nations health agency said it will work with regional partners to tell national health authorities about the two-dose shot and its anticipated benefits.

The WHO established its emergency use listing (EUL) process to help poorer countries without their own regulatory resources quickly approve medicines new diseases like COVID-19, which otherwise could lead to delays.